Skip to main content

Table 2 Incremental costs, QALYs gained and ICERs for the total New Zealand adult population including a subset of the population with high risk of gastric cancer (Māori), comparing serology and fecal antigen as the screening test, in 2011 with lifetime follow-up of participants

From: A screening program to test and treat for Helicobacter pylori infection: Cost-utility analysis by age, sex and ethnicity

Model output Total population
25–69 yo
Māori
25-69 yo
Non-Māori
25–69 yo
Serology based screening
 Men and women
  Number cases of gastric cancer averted 3658 (1252–4425) 1007 (342–1828) 2650 (905–4837)
  Percentage cases of gastric cancer averted 16.5% (5.6%–29.4%) 21.6% (7.4%–38.6%) 15.2% (5.2%–27%)
  Number of gastric cancer deaths averted 2434 (834–4425) 714 (242–1293) 1720 (588–3141)
  Percentage gastric cancer deaths averted 16.6% (5.7%–29.5%) 21.6% (7.3%–38.6%) 15.2% (5.2%–27%)
  Total net incremental cost (NZ$ million) $293 ($272–$314) $41 ($35–$46) $252 ($233–$272)
   Total intervention cost (NZ$ million) $294 ($282–$307) $41 ($38–$45) $253 ($242-$264)
   Total cost offsets (NZ$ million) -$1.5 (-$26.2–$22.9) -$0.61 (-$7.35–$6.21) -$0.89 ($-22.7–$21.7)
  Total QALYs gained 14,200 (5100–26,300) 4000 (1400–7400) 10,200 (3653–18974)
  Incremental net cost per participant (NZ$) $119 ($111–$128) $137 ($117–$158) $117 ($108–$126)
  Incremental QALYs gained per participant 0.0058 (0.0020–0.0107) 0.0137 (0.0047–0.0252) 0.0047 (0.0016–0.0087)
  ICER (NZ$ per QALY gained) $24,600 ($11,300–$57,400) $12,000 ($5700–$27,600) $29,600 ($13,400–$69,800)
 Men
  Incremental cost per participant (NZ$) $123 ($113–$134) $147 ($123–$173) $120 ($110–$131)
  Incremental QALYs gained per participant 0.0071 (0.0024–0.0131) 0.0158 (0.0055–0.0293) 0.0059 (0.0020–0.0110)
  ICER (NZ$ per QALY gained) $20,800 ($9800–$47,900) $11,000 ($5600–$24,300) $24,300 ($11,300–$57,100)
 Women
  Incremental cost per participant (NZ$) $116 ($108–$124) $129 ($110–$148) $114 ($105–$123)
  Incremental QALYs gained per participant 0.0046 (0.0016–0.0085) 0.0118 (0.0040–0.0217) 0.0036 (0.0012–0.0067)
  ICER (NZ$ per QALY gained) $30,200 ($13, 400–$71,400) $13,200 ($5900–$31,300) $38,000 ($16,800–$89,900)
Fecal antigen based screening
 Men and women
  Total incremental cost (NZ$ million) $369 ($350–$389) $49 ($44–$55) $320 ($301–$339)
  Total QALYs gained 15,300 (5400–27,700) 4200 (1500–7600) 11,000 (3830–20,200)
  Incremental cost per participant (NZ$) $150 ($142–$158) $164 ($147–$182) $148 ($139–$156)
  Incremental QALYs gained per participant 0.0061 (0.0022–0.0111) 0.0142 (0.0051–0.0259) 0.0050 (0.0018–0.0092)
  ICER (NZ$ per QALY) $29,000 ($13,600–$65,900) $13,700 ($6700–$30,500) $34,900 ($16,300–$79,100)
  1. Central estimates are the mean from the probabilistic sensitivity analysis Monte Carlo simulations and the brackets indicate the 95% uncertainty intervals
  2. QALY quality-adjusted life year with disability weights, ICER incremental cost-effectiveness ratio